IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
ENTHESITIS AND DACTYLITIS

EMERGE TREMFYANTTM : COMPLETE RESOLUTION OF ENTHESITIS AT WEEK 241-3

LEI=Leeds Enthesitis Index.
*Among patients with LEI enthesitis score >0 at baseline.
Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders. 
§After Week 24, patients and doctors knew that all patients were on TREMFYA® (open-label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analysis from Weeks 24 to 52 is not shown.

EMERGE TREMFYANTTM : COMPLETE RESOLUTION OF DACTYLITIS AT WEEK 241-3

*Among patients with dactylitis at baseline.
Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders. 
§After Week 24, patients and doctors knew that all patients were on TREMFYA® (open-label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analysis from Weeks 24 to 52 is not shown.

References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136.